tiprankstipranks
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA

MRKR Stock Latest News

Buy Rating Maintained for Marker Therapeutics Due to Promising MT-601 Developments and APOLLO Study Progress
RatingsBuy Rating Maintained for Marker Therapeutics Due to Promising MT-601 Developments and APOLLO Study Progress
11d ago
MRKR
Marker Therapeutics Reports Positive Impact of Lymphodepletion on MAR-T Cells
PremiumCompany Announcements
Marker Therapeutics Reports Positive Impact of Lymphodepletion on MAR-T Cells
11d ago
MRKR
Marker Therapeutics reports evidence from Phase 1 APOLLO study
PremiumThe Fly
Marker Therapeutics reports evidence from Phase 1 APOLLO study
12d ago
MRKR
Marker Therapeutics Advances T Cell Therapies in 2024
PremiumCompany Announcements
Marker Therapeutics Advances T Cell Therapies in 2024
1M ago
MRKR
Marker Therapeutics: Strong Buy Rating Backed by Innovative MAR-T Cell Therapy and Robust Financial Position
PremiumRatings
Marker Therapeutics: Strong Buy Rating Backed by Innovative MAR-T Cell Therapy and Robust Financial Position
2M ago
MRKR
Marker Therapeutics Advances MT-601 with Promising Results and Strategic Funding
PremiumCompany AnnouncementsMarker Therapeutics Advances MT-601 with Promising Results and Strategic Funding
2M ago
MRKR
Marker Therapeutics reports FY24 EPS ($1.19) vs ($1.59) last year
Premium
The Fly
Marker Therapeutics reports FY24 EPS ($1.19) vs ($1.59) last year
2M ago
MRKR
Marker Therapeutics initiated with a Buy at Canaccord
Premium
The Fly
Marker Therapeutics initiated with a Buy at Canaccord
3M ago
MRKR
Marker Therapeutics initiated with a Buy at Canaccord
PremiumThe Fly
Marker Therapeutics initiated with a Buy at Canaccord
3M ago
MRKR
Marker Therapeutics Grants Stock Options to Directors
PremiumCompany Announcements
Marker Therapeutics Grants Stock Options to Directors
3M ago
8K
MRKR
Marker Therapeutics initiated with a Buy at Brookline
PremiumThe Fly
Marker Therapeutics initiated with a Buy at Brookline
4M ago
MRKR
Marker Therapeutics files to sell 10.06M shares of common stock for holders
PremiumThe Fly
Marker Therapeutics files to sell 10.06M shares of common stock for holders
5M ago
MRKR
Biotech Alert: Searches spiking for these stocks today
PremiumThe FlyBiotech Alert: Searches spiking for these stocks today
5M ago
MRK
NVO
Marker Therapeutics sells 5.03M shares at $3.20 in private placement
Premium
The Fly
Marker Therapeutics sells 5.03M shares at $3.20 in private placement
5M ago
MRKR
Marker Therapeutics provides update on MT-601 patients
Premium
The Fly
Marker Therapeutics provides update on MT-601 patients
5M ago
MRKR
Marker Therapeutics awarded $9.5M grant from CPRIT
PremiumThe Fly
Marker Therapeutics awarded $9.5M grant from CPRIT
6M ago
MRKR
Marker Therapeutics files $300M mixed securities shelf
PremiumThe Fly
Marker Therapeutics files $300M mixed securities shelf
6M ago
MRKR
Marker Therapeutics Advances in Clinical Trials and Finances
PremiumCompany Announcements
Marker Therapeutics Advances in Clinical Trials and Finances
7M ago
MRKR
Marker Therapeutics price target raised to $19 from $11 at Ladenburg
PremiumThe Fly
Marker Therapeutics price target raised to $19 from $11 at Ladenburg
7M ago
MRKR
Marker Therapeutics Excels in Lymphoma Treatment Study
PremiumCompany AnnouncementsMarker Therapeutics Excels in Lymphoma Treatment Study
10M ago
MRKR
Marker Therapeutics Receives $2M NIH Grant for Lymphoma Study
Premium
Company Announcements
Marker Therapeutics Receives $2M NIH Grant for Lymphoma Study
10M ago
MRKR
Marker Therapeutics awarded $2M grant from NIH SBIR program
Premium
The Fly
Marker Therapeutics awarded $2M grant from NIH SBIR program
10M ago
MRKR

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >